Inclusion Criteria:  Voluntarily participate, and sign the informed consent form; Age ≥ 18 and ≤ 80 years, regardless of sex; Patients after completion of planned percutaneous coronary intervention for 4 weeks.  Exclusion Criteria:  Allergic to colchicine, tranilast or oridonin; Taking colchicine, tranilast or oridonin before the screening period (10 days); Abnormal liver function (ALT > 3 times the upper limit of normal value); Abnormal renal function (creatinine clearance < 45 ml / min); Thrombocytopenia (PLT < 100g / L); Uncontrolled infectious diseases; Complicated with immune diseases or immune related diseases such as systemic lupus erythematosus, asthma, inflammatory bowel disease, gout, and malignant tumor, etc. Nonsteroidal anti-inflammatory drugs, hormones, immunomodulatory and chemotherapeutic drugs been taken; History of surgery within 6 months before the screening period; Pregnant women, lactating women or women of childbearing age who do not use effective contraceptives; Other circumstances in which the investigator judges that the patient is not suitable to participate in the clinical trial.